Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Total Synthesis of GKK1032A2 via Direct 13-Membered Macrocyclization Using a Nucleophilic Aromatic Substitution of an (η⁶-Arene)Chromium Complex.

Autor: Sugata, Hayato, Inagaki, Kensuke, Ode, Toshiaki, Hayakawa, Tomoki, Karoji, Yuki, Baba, Motoaki, Kato, Ryo, Hasegawa, Daiju, Tsubogo, Tetsu, Uchiro, Hiromi

Publikováno v: Chemistry - An Asian Journal; 3/16/2017, Vol. 12 Issue 6, p628-632, 5p

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.

Autor: Watanabe Miyano S; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan.; Department of Genomics-Based Drug Discovery, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan., Yamamoto Y; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Kodama K; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Miyajima Y; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Mikamoto M; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Nakagawa T; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Kuramochi H; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Funasaka S; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Nagao S; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Sugi NH; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Okamoto K; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Minoshima Y; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Nakatani Y; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Karoji Y; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Ohashi I; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Yamane Y; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Okada T; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Matsushima T; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Matsui J; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Iwata M; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Uenaka T; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan., Tsuruoka A; Tsukuba Research Laboratories, Eisai Co., Ltd, Tsukuba-shi, Ibaraki, Japan. a-tsuruoka@hhc.eisai.co.jp.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2016 Nov; Vol. 15 (11), pp. 2630-2639. Date of Electronic Publication: 2016 Aug 17.